Biofrontera Inc BFRI

Morningstar Rating
$1.02 −0.02 (1.92%)
View Full Chart

About Quantitative Ratings

Morningstar Quantitative Ratings for Stocks are generated using an algorithm that compares companies that are not under analyst coverage to peer companies that do receive analyst-driven ratings. Companies with quantitative ratings are not formally covered by a Morningstar analyst, but are statistically matched to analyst-rated companies, allowing our models to calculate a quantitative moat, fair value, and uncertainty rating.

Price vs Fair Value

BFRI is trading at a LOCK|%!!&^ premium.
Price
$1.05
Fair Value
LOCK|lz!?gsF
Uncertainty
LOCK|@<
1-Star Price
LOCK|Xq@%nm
5-Star Price
LOCK|#fDzS?&
Economic Moat
LOCK|%&B
Capital Allocation
—

Trading Information

Previous Close Price
$1.04
Day Range
$1.01–1.12
52-Week Range
$0.55–1.66
Bid/Ask
$1.01 / $1.03
Shares Outstanding
14.85M
Market Cap
$15.15M
Volume/Avg
225,104 / 558,359

Key Statistics

Price/Earnings (Normalized)
—
Price/Sales
0.27
Dividend Yield (Trailing)
0.00%
Dividend Yield (Forward)
0.00%
Dividend Payment Schedule
—
Total Yield
—

Company Profile

Biofrontera Inc is a United States-based biopharmaceutical company commercializing a portfolio of pharmaceutical products for the treatment of dermatological conditions with a focus on photodynamic therapy. The Company's licensed products, which include Ameluz as well as the BF-RhodoLED and RhodoLED XL lamps (together, the RhodoLED Lamps), are used for the treatment of actinic keratoses (AKs), which are pre-cancerous skin lesions. The company's revenues are derived from within the United States and, therefore, no other geographical segments.
Sector
Healthcare
Industry
Drug Manufacturers - Specialty & Generic
Stock Style Box
Small Value
Total Number of Employees
94

Valuation

Metric
BFRI
Price/Earnings (Normalized)
—
Price/Book Value
2.48
Price/Sales
0.27
Price/Cash Flow
—
Price/Earnings
No chart available

Financial Strength

Metric
BFRI
Quick Ratio
0.98
Current Ratio
1.18
Interest Coverage
−12.12
Quick Ratio
BFRI

Profitability

Metric
BFRI
Return on Assets (Normalized)
−22.92%
Return on Equity (Normalized)
−169.71%
Return on Invested Capital (Normalized)
−51.52%
Return on Assets
BFRI

Drug Manufacturers - Specialty & Generic Industry Comparables

1-Day Chart
Name
Price
Morningstar Rating for Stocks
Capital Allocation
Economic Moat
Market Cap
Merck KGaA ADR
MKKGY
LOCK|!n$%D!WzLOCK|J?ZB$66B
Teva Pharmaceutical Industries Ltd
TEVA
LOCK|my%DG<sLOCK|>Sy<$46B
Haleon PLC ADR
HLN
LOCK|n?Y!WRBLOCK|sW$38B
Zoetis Inc Class A
ZTS
LOCK|$B%??$<>LOCK|fp$29B
Viatris Inc
VTRS
LOCK|Z<wVBFLOCK|RN$20B
Elanco Animal Health Inc
ELAN
LOCK|VQLOCK|By$11B
Dr Reddy's Laboratories Ltd ADR
RDY
LOCK|ZpT#g?LOCK|NPd$10B
Hims & Hers Health Inc Ordinary Shares - Class A
HIMS
LOCK|ScTmFfLOCK|Z>S$7B
Prestige Consumer Healthcare Inc
PBH
LOCK|Hcn?>XLOCK|m^K@C$2B
Perrigo Co PLC
PRGO
LOCK|Yv?H@ZMLOCK|FTX$2B

Sponsor Center